FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments. ...

About Enzo Biochem Exhibit 99.1 Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights "Enzo's strategy is to deliver sustainable, profitable revenue growth through market focus, technical strength, and operational conservatism. We are pleased to report a third co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of (IRS. Employer Incorporation or Organization) Identification No.) 81 Executive Blvd. Suite 3 Farmingdale, New York 11735 (Address of Principal Executive office) (Zip Code) Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ ...

FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fisc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) FORM 10-K New York 13-2866202 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 81 Executive Blvd. Suite 3 (Mark one) ☒ ANNUAL REP ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York ...

Enzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Conference Call December 13, 2022 8:30 AM ET Company Participants Unidentified Company Representative - IR Hamid Erfanian - CEO Patricia Eckert - Interim CFO Conference Call Participants Operator Greetings and welcome to the Enzo Biochem, Incorporated First Quarter 2023 Earnings Call. At this all participants are in a listen-only mode. [Operator Instructions]. Please note that this conference is being recorded. At this time I will turn the conference over to Br ...

Revenue Performance - For the three months ended October 31, 2022, revenues decreased to $18.276 million, down 31% from $26.519 million in the same period of 2021[140] - Clinical services revenues decreased to $11.2 million in 2023 from $19.7 million in 2022, a decline of 43%[147] - Revenues from COVID-19 testing represented 7% of clinical revenues in 2023, down from 47% in 2022, with a 92% decline in COVID-19 accessions[147] - Product revenues increased to $7.1 million in 2023, up 5% from $6.8 million in 2022, with growth in the U.S. and Asia Pacific regions[150] Operating Loss and Costs - Operating loss for the three months ended October 31, 2022, was $9.913 million, compared to an operating loss of $1.832 million in the same period of 2021, reflecting an unfavorable change of $8.081 million[140] - Total operating costs and expenses for the three months ended October 31, 2022, were $28.189 million, a slight decrease of 1% from $28.351 million in the same period of 2021[140] - The cost of clinical services decreased to $10.1 million in 2023, down 10% from $11.2 million in 2022, resulting in a gross profit margin of approximately 10%[151] Cash Flow and Liquidity - Net cash used in operating activities was $8.7 million in 2023, compared to $6.0 million in 2022, reflecting a net loss of $10.6 million[163] - The company had cash and cash equivalents of $12.1 million as of October 31, 2022, down from $21.6 million at July 31, 2022[160] - The company believes its current cash and cash equivalents are sufficient for its liquidity needs over the next twelve months, but may need to raise additional capital if losses continue[168] Accounts Receivable - As of October 31, 2022, approximately 62% of the Company's net accounts receivable relates to its Clinical Laboratory Services business, up from 59% as of July 31, 2022[180] - The Clinical Labs segment's total net accounts receivable increased to $7.096 million as of October 31, 2022, from $6.754 million as of July 31, 2022[181] - Accounts receivable from third-party payers in the Clinical Labs segment rose to $3.054 million (43%) as of October 31, 2022, compared to $2.647 million (40%) as of July 31, 2022[181] - The Company reported total net accounts receivable of $11.515 million as of October 31, 2022, nearly unchanged from $11.516 million as of July 31, 2022[181] Research and Development - The company has a substantial portfolio of approximately 472 issued patents worldwide and over 64 pending patent applications, supporting its R&D efforts[134] - Research and development expenses rose to $1.0 million in 2023, an increase of 34% from $0.7 million in 2022, focusing on lab-developed tests and COVID-19 detection[154] Market and Economic Conditions - The company continues to assess the potential adverse impacts of the recessionary economic environment on its financial position and cash flows[129] - The company expects that volume and revenues from COVID-19 testing will remain less significant as vaccination rates increase and the severity of variants declines[128] Currency Risk - The Company is exposed to a potential $2.0 million unfavorable impact on pre-tax earnings annually if the U.S. dollar appreciates by 10% against foreign currencies[192] - A hypothetical 10% increase in the U.S. dollar value would decrease the Company's net revenues and net income by $0.8 million and $0.5 million, respectively, on an annual basis[191] - The Company does not currently engage in any hedging or market risk management tools to mitigate foreign currency exchange rate risks[190] Operational Challenges - Enzo's Clinical Services segment is impacted by reduced reimbursements from third-party payers and recent healthcare legislation[136] - Selling, general and administrative expenses increased to $11.5 million in 2023, a rise of 4% from $11.1 million in 2022, primarily due to higher facility costs[155] - Enzo's proprietary technology platforms aim to reduce overall healthcare costs and improve accuracy and reproducibility in diagnostic testing[133] - The Company assesses the collectability of receivables based on the quality of its billing processes, which are critical for operating performance and cash flows[181]